Stereotaxis Epoch™ Solution`s Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting

More Than 1,250 Niobe® ES (Epoch™ Solution) Cases Completed Stereotaxis, Inc. will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch™ platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012. The formal HRS academic program features multiple invited presentations, podium presentations, and posters detailing Stereotaxis' clinical results in a wide variety of arrhythmias. A total of 11 invited podium presentations feature use of Stereotaxis magnetic navigation technology. In addition, 13 submitted abstracts that feature or discuss Stereotaxis technology are included in this year's HRS program. Highlights of these submitted abstracts include comparative data on VT ablation, multi-center VT data, lesion formation, pediatric outcome data, and the first large series of Vdrive™ system's clinical outcomes data. Stereotaxis will be at booth number 1307, providing demonstrations of commercially available products and a technical suite for obtaining input on new product innovations from select physician customers. In addition, the Company will feature at the booth a speaker series where customers will share their experiences with the Epoch™ and Odyssey™ product platforms. In-booth speakers include: * Dr. Robert Schweikert from Akron General Medical Center on the Odyssey™ Solution (May 10 at 9:30 am ET); * Dr. Yaariv Khaykin from Southlake Regional Health Center on the Odyssey™ Solution (May 10 at 10:00 am ET); and * Dr. J. Peter Weiss from Intermountain Medical Center on the Epoch™ Solution (May 10 at 3:45 pm ET and May 11 at 10:00 am ET). Stereotaxis will unveil a broad number of product innovations for the Niobe® ES, Vdrive™ and Odyssey™ platforms scheduled to be shipped in 2012. The innovations include advancements in linear line formation and testing, Vdrive™ offering and Odyssey™ remote collaboration. "Stereotaxis will launch exciting advancements at the upcoming HRS congress, which will further enhance the value we bring to the EP market," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. The 2012 innovations for the Niobe® ES and Odyssey™ product platforms as well as the new Vdrive™ platform demonstrate our continued commitment to providing new solutions for the EP market." About Stereotaxis Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables. The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.